DCN and hepatoblastoma: We identified high levels of IGF2 in patients enriched for Hepatoblastoma I and Hepatoblastoma II signatures (Fig. 2h, i, m), GATA1 in patients enriched for the Erythroid-like signature (Fig. 2j, m), POSTN in patients enriched for the DCN-high signature (Fig. 2k, m), and CHGA in patient 8 who was enriched in the Neuroendocrine signature (Fig. 2l, m).